ISSN: 1359-6446

Journal Home

Journal Guideline

Drug Discovery Today Q1 Unclaimed

Elsevier Ltd. United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drug Discovery Today is a journal indexed in SJR in Drug Discovery and Pharmacology with an H index of 175. It has a price of 2395 €. It has an SJR impact factor of 1,778 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,778.

Drug Discovery Today focuses its scope in these topics and keywords: drug, library, cancer, discovery, clinical, development, drugs, data, crowd, class, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Drug Discovery (Q1) Pharmacology (Q1)

Price

2395 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,778

SJR Impact factor

175

H Index

258

Total Docs (Last Year)

667

Total Docs (3 years)

19752

Total Refs

5142

Total Cites (3 years)

630

Citable Docs (3 years)

7,17

Cites/Doc (2 years)

76,56

Ref/Doc

Other journals with similar parameters

Nature Reviews Drug Discovery Q1
Perspectives in Medicinal Chemistry Q1
Molecular Therapy Q1
Cell Chemical Biology Q1
Protein & Cell Q1

Compare this journals

Aims and Scope

Best articles by citations

New antibody therapies for HIV

Chemokines and their receptors

Sweet signal transduction

Project acceleration - the case for quantum change

Dizzying but scary: looking towards R&D in 2005

Targeted molecular diversity in drug discovery: Integration of structure-based design and combinatorial chemistry

Challengeability of biotechnology patents in the light of Biogen v. Medeva

Could insulin protect against atherosclerosis?

Passion versus fear as the emotion driving scientists

Using the power of developmental biology for drug discovery

Project Management for Successful Product Innovation

Preparation of secondary amines

SHOW MORE ARTICLES

Chiral Europe '95

People

Targeted taxane therapy for cancer

People

Working with worms

Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery

Antimalarial drug discovery: development of inhibitors of dihydrofolate reductase active in drug resistance

Beating superbugs with the Gulliver effect

Monitor and Molecules

Erratum

Monitor: molecules and profiles

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .